KARAMBIOSCIENCE
EST. 2026
EVIDENCE / 02
Concept illustrations comparing gene regulation, epigenome, base and prime editing.
CRISPR / Field guide
Research context · Assessment edition 15 October 2026

Base editing vs prime editing: what should determine the choice?

The desired sequence change, tissue, delivery route and outcome measurement matter more than a platform label.

Concept illustration / not experimental evidence

A defined sequence question comes first

Base editing performs selected chemical conversions of DNA letters, generally without a deliberate double-strand break. Prime editing uses a nickase, reverse transcriptase and specialized guide that includes a template for a change.

The assessment treats these as candidates when a specific causal sequence defect and workable delivery route have been identified. Neither is a general-purpose explanation of how to reverse normal aging.

[C05] [C06] [C09] [C14]

What prime-editing advances demonstrate

The Korean large-fragment study described in the assessment included targeted insertion in primary human T cells. That application must remain separate from performance maxima in cell lines and different mouse delivery settings.

The lipid-nanoparticle work involved mouse-liver and cellular settings, including a disease model. It demonstrates that cargo and delivery can affect performance, not that the approach reaches all human tissues.

[C05] [C06] [C09] [C14]

Prediction does not replace measurement

OptiPrime is an example of mechanistic machine learning used to predict prime-editing outcomes. Prediction may narrow a search, but experimental confirmation and context-specific comparison remain necessary.

A separate publication check for this website found that the publisher’s code-availability section labels the OptiPrime code and hosted server as noncommercial-use only. A public tool is not automatically licensed for a paid workflow.

[C05] [C06] [C09] [C14]

Judge the complete outcome

Useful comparison requires intended alleles, other sequence changes, structural outcomes, the assay’s blind spots and biological function. Editing percentage alone does not establish genome integrity or a therapeutic benefit.

The public comparison tool is an educational matrix, not an editor-selection approval. A real program requires a qualified team to connect the sequence objective with delivery, measurement, rights and an appropriate development path.

[C05] [C06] [C09] [C14]

Bring one question worth answering.

Tell us the decision, the evidence you have and the gap that blocks the next step. Start with nonconfidential context.